The Ligand Pharmaceuticals Inc. (LGND) Upgrade to Hold by The Zacks Investment Research

Posted under Uncategorized on December 10th, 2016 by

Ligand’s Captisol formulation technology has resulted in partnerships with … The biotechnology company reported $0.62 earnings per share for the …

Leave a Comment